Those lists are garbage, IMO. For instance, ADH-1 is shown as one of the top non-partnered oncology programs, despite that fact that GSK dumped it last year.
What’s worse is that GENR’s Trodusquemine (MSI-1436) for obesity is listed as a top contender in metabolic disorders. This is a drug that’s been lying around on GENR’s back burner for 15 years and has never been subjected to any medicinal chemistry. The reason it’s finally in clinical trials after all these years is that everything else the company has tried has flopped.
Market Data 
Markets 
AI
